Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting

Fundació Institut Català de Farmacologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
British Journal of Clinical Pharmacology (Impact Factor: 3.88). 11/2010; 70(5):656-63. DOI: 10.1111/j.1365-2125.2010.03743.x
Source: PubMed


Despite progress in anti-emetic treatment, many patients still suffer from chemotherapy-induced nausea and vomiting (CINV). This is a pilot, randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate the tolerability, preliminary efficacy, and pharmacokinetics of an acute dose titration of a whole-plant cannabis-based medicine (CBM) containing delta-9-tetrahydrocannabinol and cannabidiol, taken in conjunction with standard therapies in the control of CINV.
Patients suffering from CINV despite prophylaxis with standard anti-emetic treatment were randomized to CBM or placebo, during the 120 h post-chemotherapy period, added to standard anti-emetic treatment. Tolerability was measured as the number of withdrawals from the study during the titration period because of adverse events (AEs). The endpoint for the preliminary efficacy analysis was the proportion of patients showing complete or partial response.
Seven patients were randomized to CBM and nine to placebo. Only one patient in the CBM arm was withdrawn due to AEs. A higher proportion of patients in the CBM group experienced a complete response during the overall observation period [5/7 (71.4%) with CMB vs. 2/9 (22.2%) with placebo, the difference being 49.2% (95% CI 1%, 75%)], due to the delayed period. The incidence of AEs was higher in the CBM group (86% vs. 67%). No serious AEs were reported. The mean daily dose was 4.8 sprays in both groups.
Compared with placebo, CBM added to standard antiemetic therapy was well tolerated and provided better protection against delayed CINV. These results should be confirmed in a phase III clinical trial.

Download full-text


Available from: Joan-Ramon Laporte,
60 Reads
  • Source
    • "These results suggest that allosteric inhibition of 5-HT 3 receptors by CBD may also contribute to modulation of emesis by this agent. There is initial proof that in patients suffering from intractable CINV, addition of Sativex ® (GW Pharmaceuticals , UK), a combination of THC and CBD, during the 5 days postchemotherapy period to the standard antiemetic regime may have a better consequence (Duran et al., 2010). However, longer treatment for 14 days in this combination produced a significant worsening in nausea and vomiting, whereas THC extract did not differ in this respect from placebo (Johnson et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cannabinoids (the active constituents of Cannabis sativa) and their derivatives have got intense attention during recent years because of their extensive pharmacological properties. Cannabinoids first developed as successful agents for alleviating chemotherapy associated nausea and vomiting. Recent investigations revealed that cannabinoids have a wide range of therapeutic effects such as appetite stimulation, inhibition of nausea and emesis, suppression of chemotherapy or radiotherapy-associated bone loss, chemotherapy-induced nephrotoxicity and cardiotoxicity, pain relief, mood amelioration, and last but not the least relief from insomnia. In this exploratory review, we scrutinize the potential of cannabinoids to counteract chemotherapy-induced side effects. Moreover, some novel and yet important pharmacological aspects of cannabinoids such as antitumoral effects will be discussed. Copyright © 2014 John Wiley & Sons, Ltd.
    Phytotherapy Research 12/2014; 29(3). DOI:10.1002/ptr.5265 · 2.66 Impact Factor
  • Source
    • "However, the growing interest in the medical applications of cannabinoids should be accompanied by discussion of their safety and efficacy in older patients (Ahmed et al., 2014). Several randomized clinical trials have demonstrated the safety and efficacy of cannabinoid-based medicines in the treatment of conditions that are common in older individuals (Nelson et al., 2004; Duran et al., 2010; Pickering et al., 2011; Toth et al., 2012). However, most of these trials either did not include older subjects or, if they were included, did not analyze data by age group, which makes it difficult to draw firm conclusions about Table 2 Overview of all 40 drug-related adverse events reported by subjects or observed by investigator during the trail. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a great concern about the safety of THC-based drugs in older people (≥65 years), as most of THC-trials did not include such group. In this phase 1, randomized, double-blind, double-dummy, placebo-controlled, cross-over trial, we evaluated the safety and pharmacokinetics of three oral doses of Namisol®, a novel THC in tablet form, in older subjects. Twelve healthy older subjects (6 male; mean age 72±5 years) randomly received a single oral dose of 3 mg, 5 mg, or 6.5 mg of THC or matching placebo, in a crossover manner, on each intervention day. The data for 11 subjects were included in the analysis. The data of 1 subject were excluded due to non-compliance to study medication. THC was safe and well tolerated. The most frequently reported adverse events (AE′s) were drowsiness (27%) and dry mouth (11%). Subjects reported more AE′s with THC 6.5 mg than with 3 mg (p=0.048), 5 mg (p=0.034) and placebo (p=0.013). There was a wide inter-individual variability in plasma concentrations of THC. Subjects for whom the Cmax fell within the sampling period (over 2 hours), Cmax was 1.42–4.57 ng/mL and Tmax was 67–92 minutes. The AUC0-2 h (n=11) was 1.67–3.51 ng/mL. Overall, the pharmacodynamic effects of THC were smaller than effects previously reported in young adults. In conclusion, THC appeared to be safe and well tolerated by healthy older individuals. Data on safety and effectiveness of THC in frail older persons are urgently required, as this population could benefit from the therapeutic applications of THC.
    European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 09/2014; 24(9). DOI:10.1016/j.euroneuro.2014.06.007 · 4.37 Impact Factor
  • Source
    • "CBD BDS is one of the main components of Sativex ( Nabixi - mols in the USA ) , a cannabinoid formulation actually used for the treatment of pain and spasticity associated with multiple sclerosis . Clinical studies have shown that Sativex may provide a protec - tion against chemotherapy - induced nausea and vomiting ( Duran et al . 2010 ) and may be a useful add - on analgesic for patients with opioid - refractory cancer pain ( Johnson et al . 2010 , 2012 ; Portenoy et al . 2012 ) . In the present study we have shown , for the first time , that CBD BDS exerts antiproliferative effects in carcinoma cell lines and attenuates colon carcinogenesis in vivo ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Colon cancer is a major public health problem. Cannabis-based medicines are useful adjunctive treatments in cancer patients. Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS, i.e. CBD botanical drug substance, on colorectal cancer cell proliferation and in experimental models of colon cancer in vivo. Proliferation was evaluated in colorectal carcinoma (DLD-1 and HCT116) as well as in healthy colonic cells using the MTT assay. CBD BDS binding was evaluated by its ability to displace [(3)H]CP55940 from human cannabinoid CB1 and CB2 receptors. In vivo, the effect of CBD BDS was examined on the preneoplastic lesions (aberrant crypt foci), polyps and tumours induced by the carcinogenic agent azoxymethane (AOM) as well as in a xenograft model of colon cancer in mice. CBD BDS and CBD reduced cell proliferation in tumoral, but not in healthy, cells. The effect of CBD BDS was counteracted by selective CB1 and CB2 receptor antagonists. Pure CBD reduced cell proliferation in a CB1-sensitive antagonist manner only. In binding assays, CBD BDS showed greater affinity than pure CBD for both CB1 and CB2 receptors, with pure CBD having very little affinity. In vivo, CBD BDS reduced AOM-induced preneoplastic lesions and polyps as well as tumour growth in the xenograft model of colon cancer. CBD BDS attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.
    Phytomedicine: international journal of phytotherapy and phytopharmacology 12/2013; 21(5). DOI:10.1016/j.phymed.2013.11.006 · 3.13 Impact Factor
Show more